
ONO-4059 hydrochloride
CAS No. 1439901-97-9
ONO-4059 hydrochloride ( ONO4059 hydrochloride | Tirabrutinib hydrochloride | GS4059 hydrochloride )
产品货号. M11864 CAS No. 1439901-97-9
一种有效的、选择性的、第三代不可逆突变 EGFR 抑制剂。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥348 | 有现货 |
![]() ![]() |
10MG | ¥624 | 有现货 |
![]() ![]() |
25MG | ¥1021 | 有现货 |
![]() ![]() |
50MG | ¥1677 | 有现货 |
![]() ![]() |
100MG | ¥2989 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称ONO-4059 hydrochloride
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述一种有效的、选择性的、第三代不可逆突变 EGFR 抑制剂。
-
产品描述A potent, selective, third-generation irreversible inhibitor of mutant EGFR with IC50s of 1/12/5 nM for L858R-T790M/L858R/L861Q respectively; weak activity against wt EGFR (IC50=184 nM); inhibits signaling pathways and cellular growth in both EGFRm(+) and EGFRm(+)/T790M(+) mutant cell lines in vitro; exhibits tumor regression in EGFR-mutant tumor xenograft and transgenic models; orally active.Blood Cancer Phase 3 Clinical.
-
体外实验Tirabrutinib hydrochloride (0.1-1000 nM or 0.001-100 nM; 72 h) inhibits the proliferation of OCI-L Y10 and SU-DHL-6 cells with IC50s of 9.127 nM, and 17.10 nM, respectively.Tirabrutinib hydrochloride (0.5, 5, 50 μM; 24, 48 h) induces SU-DHL-6 cells apoptosis needs high dosage and prolonged administration (concentration up to 50 μM and incubates for 48 h).Tirabrutinib hydrochloride (300 nM, 72 h) induces caspase-3 and PARP cleavage in TMD8 cells. Cell Proliferation Assay Cell Line:SU-DHL-6 and OCI-L Y10 cells Concentration:0.1-1000 nM; 0.001 nM-100 nM.Incubation Time:72 h Result:Showed good anti-proliferative activity with IC50s of 9.127 nM, and 17.10 nM for OCI-L Y10 and SU-DHL-6 cells, respectively.Apoptosis AnalysisCell Line:SU-DHL-6 cellsConcentration:0.5, 5, 50 μM Incubation Time:24, 48 h Result:Induced cell apoptosis when concentration up to 50 μM and incubated for 48 h.Western Blot AnalysisCell Line:TMD8 cells Concentration:300 nM Incubation Time:72 h Result:Induced caspase-3 and PARP cleavage.
-
体内实验Tirabrutinib hydrochloride (10 mg/kg; p.o.; single) is rapidly absorbed into plasma and brain, and reaches Cmax (blood Cmax =339.53 ng/mL; brain Cmax =28.9 ng/mL) 2 hours post administration.Tirabrutinib hydrochloride (6, 20 mg/kg; p.o.; single daily for 3 weeks) shows inhibition of tumour growth in vivo. Animal Model:Male SD rats (219.0–260.5g).Animal Model:Immunodeficiency (SCID) mice (mouse xenograft model).Dosage:6, 20 mg/kg Administration:Oral administration; single daily for 3 weeks.Result:Inhibited tumour growth, and when dosage up to 20 mg/kg, a complete tumor suppression at day 14.
-
同义词ONO4059 hydrochloride | Tirabrutinib hydrochloride | GS4059 hydrochloride
-
通路Tyrosine Kinase
-
靶点BTK
-
受体BTK
-
研究领域Cancer
-
适应症Blood cancer
化学信息
-
CAS Number1439901-97-9
-
分子量490.9415
-
分子式C25H23ClN6O3
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESCC#CC(=O)N1CCC(C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N.Cl
-
化学全称8H-Purin-8-one, 6-amino-7,9-dihydro-9-[(3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-, hydrochloride (1:1)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Walter HS, et al. Blood. 2016 Jan 28;127(4):411-9.
2. Yahiaoui A, et al. PLoS One. 2017 Feb 8;12(2):e0171221.
3. Yasuhiro T, et al. Leuk Lymphoma. 2017 Mar;58(3):699-707.
产品手册




关联产品
-
KS-99
KS-99 (KS99) 是一种新型的 BTK 和微管蛋白聚合双重抑制剂。
-
BTK-IN-16
BTK-IN-16 是 Bruton’s tyrosine kinase (BTK) 的 BTK wild type 和 C481S mutant 的抑制剂,其 IC50 值分别为 5.1 和 4.1 μM。BTK-IN-16 可用于自身免疫疾病和慢性淋巴细胞白血病的研究。
-
JAK3/BTK-IN-1
JAK3/BTK-IN-1 是一种有效的 JAK3/BTK 抑制剂。BTK 和 JAK3 是自身免疫性疾病的两个重要靶点。同时抑制 BTK/JAK3 信号通路表现出协同效应。JAK3/BTK-IN-1具有研究J AK3 激酶和/或 BTK 相关疾病的潜力 (摘自专利 WO2021147952A1,化合物 002)。